Polymerase Chain Reaction (PCR) Market Expansion in Infectious Disease Testing – 2032 Forecast
Polymerase Chain Reaction (PCR) Market Expansion in Infectious Disease Testing – 2032 Forecast
The Polymerase Chain Reaction (PCR) market is expanding steadily as demand grows for precise molecular testing across healthcare, academic research, diagnostics, forensics, and biotechnology. PCR is essential for amplifying DNA/RNA segments, enabling accurate detection of genetic diseases, infectious pathogens, and cancer biomarkers. Technological advancements—including real-time PCR, digital PCR, and portable point-of-care systems—are boosting the market, supported by rising healthcare investments and a global focus on early diagnosis and disease surveillance. As applications diversify and access increases, the PCR market is poised for sustained growth worldwide.
According to Fortune Business Insights, the global polymerase chain reaction (PCR) market was valued at USD 9.15 billion in 2023 and is projected to grow from USD 9.91 billion in 2024 to USD 19.23 billion by 2032, exhibiting a CAGR of 8.6% during the forecast period. In 2023, North America dominated the PCR market with a market share of 40%.
Bio‑Rad Laboratories, Inc. (California, U.S.)
QIAGEN (Hilden, Germany)
F. Hoffmann‑La Roche Ltd (Basel, Switzerland)
Agilent Technologies, Inc. (California, U.S.)
Abbott (Illinois, U.S.)
Eppendorf AG (Hamburg, Germany)
Sysmex Inostics (Hyogo, Japan)
Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
BD (New Jersey, U.S.)
In November 2023, F. Hoffmann‑La Roche Ltd launched its next-generation qPCR system, the LightCycler PRO System. Designed to address advanced molecular diagnostic needs, it brings enhanced automation, multiplexing capacity, and improved data integrity .
Surging Infectious Disease Burden: Rising cases of tuberculosis, COVID‑19, and other pathogens necessitate rapid, accurate molecular diagnostics. With over 10 million TB cases in 2022 and 236 million COVID‑19 cases by late 2021, PCR remains critical for early detection .
Technological Innovation: The PCR market is witnessing a shift from real‑time to digital platforms, offering better sensitivity, quantification, and multiplexing capability. For instance, Stilla Technologies' Nio+ digital PCR launched in November 2023 .
Expanded R&D and Forensics: PCR's versatility in drug discovery, genetic testing, and forensic applications continues to fuel demand, prompting global innovation .
COVID‑19 Stimulus: The pandemic triggered a massive increase in PCR testing worldwide—propelling demand for reagents, instruments, and workflows .
High Cost in Emerging Markets: Expensive reagent kits and lack of awareness limit PCR adoption in low- and middle-income countries. For example, PCR testing in Kansai, Japan (~USD 404) cost over twice that in New York (~USD 179) .
Complex Infrastructure Needs: PCR requires specialized instruments and reliable cold-chain logistics, which can pose a barrier for remote and resource-limited areas.
The PCR market report offers extensive insights, including:
Type-based segmentation: standard PCR, real-time PCR, and digital PCR
Product categories: instruments vs reagents & consumables
Indications: infectious diseases, oncology, genetic disorders, and others
End users: hospitals & clinics, diagnostic centers, pharma & biotech, academic & research facilities
Regional breakdown: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Market drivers, trends, restraints, and competitive strategies
The PCR market is highly consolidated, led by Bio‑Rad, QIAGEN, Roche, and Thermo Fisher. Key strategies include:
Product Innovation: Launches like Roche’s LightCycler PRO, Bio‑Rad’s droplet digital systems, and QIAGEN’s real-time platforms demonstrate aggressive innovation .
Strategic Alliances: Collaborations among PCR providers and diagnostic labs have intensified during COVID‑19, improving test deployment efficiency.
Acquisitions: Companies are acquiring smaller innovators—for example, Bio‑Rad’s integration of PathStore and QuantuMDx—to expand capabilities .
Real-time PCR remains the most widely used segment due to its balance of cost, throughput, and clinical adoption, especially during COVID‑19 . Meanwhile, Digital PCR is growing rapidly, offering unparalleled precision and quantification for applications like mutation detection .
Reagents & Consumables dominate market share due to ongoing test volume requirements. Instruments, comprising thermocyclers and droplet systems, grow steadily due to innovation investment .
Infectious Diseases—including TB, COVID‑19, and influenza—lead usage due to high demand and rapid turnaround time . Growing cancer genomics and hereditary disorder testing is increasing demand in oncology and genetic segments.
Diagnostic centers hold the largest share thanks to their high adoption rates and reimbursement support. Pharma & biotech, research institutions, and academic labs also contribute to market growth via R&D activities.
Holding 40% share (~USD 3.66 billion in 2023), North America leads due to advanced diagnostics infrastructure, strong reimbursement policies, and widespread PCR acceptance.
Europe ranks second, with rising chronic disease detection efforts and growing demand for precise cancer diagnostics.
Fastest-growing region driven by COVID‑19 testing ramp-up, expansion of research infrastructure in China, India, Japan, and emerging markets pushing PCR adoption.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/polymerase-chain-reaction-pcr-market-102528
The PCR market is set for continued expansion, fueled by:
Wider uptake of digital PCR for precision diagnostics and biomarker quantification
Portable, point-of-care PCR systems for rapid, field-based testing
Integration with next-gen sequencing (NGS) to enhance molecular diagnostic pipelines
Growing use in personalized medicine and biomarker-driven drug development
In summary, the PCR market is charting a strong upward trajectory—from USD 9.15 billion in 2023 to nearly USD 19.23 billion by 2032. Fueled by infectious disease diagnostics, oncology, and R&D investments, the market is being reshaped by digital technologies, novel reagent kits, and POC systems. As clinical requirements evolve, PCR leaders like Bio-Rad, QIAGEN, Roche, and Thermo Fisher are set to define the next wave of molecular innovation.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com